Since the ancient Egyptians learned how to trephine the cranium, there has been only minimal progress with regard to the treatment of neurological problems. Concussion particularly has persisted throughout the centuries without a viable therapeutic solution regardless of activities, environmental factors and the coexistence of other disease entities.
Recently, this problem has achieved a greater profile as it affects highly paid professional athletes and is often responsible for cognitive disabilities, disruptive behavior patterns and other problems resulting from impacts sustained during athletic activities, particularly in contact sports.
There are many variations of this problem, from minimal to severe and symptoms can negatively impact activity levels, mentation and destroy the quality of life. The effects of this trauma include progressive dysfunctional behavior patterns, many other symptoms, sometimes in unusual combinations and may even lead to suicide. Post-Traumatic Stress Disorder, which not infrequently includes a history of concussion, should also be added to the list of these pathologies.
Although diagnostic techniques have advanced through the introduction and refinements in interpretation of EEGs, MRIs, PET scans, etc. along with improvement in medical education, therapeutic solutions remain elusive or largely ineffective. The need to find effective therapies for these problems has stimulated our interest and efforts in order to provide viable solutions. The therapeutic aspect of dealing with these diseases clearly must improve and can only be achieved through the process of innovation.
At Meditech, over the past decade particularly, we have been acutely aware of this problem and more recently, supported by a number of neuroscientists, we are in the process of developing effective therapeutic techniques, delivered without adverse components.
At this time we feel that we have made significant progress in this area and continue our research in the effort to improve the development of protocols that relieve symptoms without creating negative effects. To date we are encouraged with the significant symptomatic improvement in patients utilizing Laser Therapy that either had no solutions offered to them previously or had been treated with conventional approaches for many years without any viable benefit.
Meditech International was founded in 1989 and early on the principals directing research recognized these problems. Its products therefore are always designed to have an almost unlimited range of flexibility in applying effective therapy. Parameters can be configured in an infinite number of permutations and combinations to produce protocols that are disease specific. At the same time, Meditech devices permit the extensive customization of protocols for each individual patient. This is of extreme importance and unfortunately is not well recognized within the industry.
In the past year or two, increasingly we see Class IV and higher powered lasers in general being aggressively marketed. In the majority of these devices, the light sources are removed some distance from the tissues in order to avoid damaging the latter. This raises the problem of refraction, as light encounters the epidermis. It should be noted that the light source in Class IV Lasers is invariably covered by plastic or glass in order to avoid burning or otherwise damaging the tissues. Whereas the light source in these systems may be powerful, an indeterminate photon stream arrives at the dermis and the joules of energy penetrating to the deeper tissues cannot be calculated and therefore produce an uncontrollable, random effect. If these arrays were placed directly on the skin, thermal damage and denaturing of the intracellular proteins would result.
Conversely, the BioFlex Laser Therapy Systems regulate the photon stream precisely without any intervention between the light source and the tissues and can therefore produce dosages with total accuracy and optimal healing effect.